A year in heart failure: updates of clinical and preclinical findings
Abstract We witnessed major advances in the management of heart failure (HF) in 2022. Results of recent clinical and preclinical investigations aid preventive strategies, diagnostic efforts, and therapeutic interventions, and collectively, they hold promises for a more effective HF care for the near...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.14377 |
| _version_ | 1797770775753654272 |
|---|---|
| author | Magnus Bäck Stephan vonHaehling Zoltán Papp Massimo F. Piepoli |
| author_facet | Magnus Bäck Stephan vonHaehling Zoltán Papp Massimo F. Piepoli |
| author_sort | Magnus Bäck |
| collection | DOAJ |
| description | Abstract We witnessed major advances in the management of heart failure (HF) in 2022. Results of recent clinical and preclinical investigations aid preventive strategies, diagnostic efforts, and therapeutic interventions, and collectively, they hold promises for a more effective HF care for the near future. Accordingly, currently available information extends the 2021 European Society of Cardiology guidelines and provides a solid background for the introduction of improved clinical approaches in the number of HF‐related cases. Elaboration on the relationships between epidemiological data and risk factors lead to better understanding of the pathophysiology of HF with reduced ejection fraction and HF with preserved ejection fraction. The clinical consequences of valvular dysfunctions are increasingly interpreted not only in their haemodynamic consequences but also in association with their pathogenetic factors and modern corrective treatment possibilities. The influence of coronavirus disease 2019 pandemic on the clinical care of HF appeared to be less intense in 2022 than before; hence, this period allowed to refine coronavirus disease 2019 management options for HF patients. Moreover, cardio‐oncology emerges as a new subdiscipline providing significant improvements in clinical outcomes for oncology patients. Furthermore, the introduction of state‐of‐the‐art molecular biologic methods, multi‐omic approaches forecast improved phenotyping and precision medicine for HF. All above aspects are addressed in this article that highlights a selection of papers published in ESC Heart Failure in 2022. |
| first_indexed | 2024-03-12T21:27:00Z |
| format | Article |
| id | doaj.art-d29f68b518b242418ed11fede811b8bd |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-03-12T21:27:00Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-d29f68b518b242418ed11fede811b8bd2023-07-28T06:30:48ZengWileyESC Heart Failure2055-58222023-08-011042150215810.1002/ehf2.14377A year in heart failure: updates of clinical and preclinical findingsMagnus Bäck0Stephan vonHaehling1Zoltán Papp2Massimo F. Piepoli3Translational Cardiology, Center for Molecular Medicine, Department of Medicine Solna Karolinska Institutet Stockholm SwedenDepartment of Cardiology and Pneumology University of Göttingen Medical Center Göttingen GermanyDepartment of Cardiology, Division of Clinical Physiology, Faculty of Medicine University of Debrecen Debrecen HungaryClinical Cardiology IRCCS Policlinico San Donato S. Donato Milanese Milan 20097 ItalyAbstract We witnessed major advances in the management of heart failure (HF) in 2022. Results of recent clinical and preclinical investigations aid preventive strategies, diagnostic efforts, and therapeutic interventions, and collectively, they hold promises for a more effective HF care for the near future. Accordingly, currently available information extends the 2021 European Society of Cardiology guidelines and provides a solid background for the introduction of improved clinical approaches in the number of HF‐related cases. Elaboration on the relationships between epidemiological data and risk factors lead to better understanding of the pathophysiology of HF with reduced ejection fraction and HF with preserved ejection fraction. The clinical consequences of valvular dysfunctions are increasingly interpreted not only in their haemodynamic consequences but also in association with their pathogenetic factors and modern corrective treatment possibilities. The influence of coronavirus disease 2019 pandemic on the clinical care of HF appeared to be less intense in 2022 than before; hence, this period allowed to refine coronavirus disease 2019 management options for HF patients. Moreover, cardio‐oncology emerges as a new subdiscipline providing significant improvements in clinical outcomes for oncology patients. Furthermore, the introduction of state‐of‐the‐art molecular biologic methods, multi‐omic approaches forecast improved phenotyping and precision medicine for HF. All above aspects are addressed in this article that highlights a selection of papers published in ESC Heart Failure in 2022.https://doi.org/10.1002/ehf2.14377Heart failureHFpEFHFrEFRisk factorsvalvular heart diseasetherapy |
| spellingShingle | Magnus Bäck Stephan vonHaehling Zoltán Papp Massimo F. Piepoli A year in heart failure: updates of clinical and preclinical findings ESC Heart Failure Heart failure HFpEF HFrEF Risk factors valvular heart disease therapy |
| title | A year in heart failure: updates of clinical and preclinical findings |
| title_full | A year in heart failure: updates of clinical and preclinical findings |
| title_fullStr | A year in heart failure: updates of clinical and preclinical findings |
| title_full_unstemmed | A year in heart failure: updates of clinical and preclinical findings |
| title_short | A year in heart failure: updates of clinical and preclinical findings |
| title_sort | year in heart failure updates of clinical and preclinical findings |
| topic | Heart failure HFpEF HFrEF Risk factors valvular heart disease therapy |
| url | https://doi.org/10.1002/ehf2.14377 |
| work_keys_str_mv | AT magnusback ayearinheartfailureupdatesofclinicalandpreclinicalfindings AT stephanvonhaehling ayearinheartfailureupdatesofclinicalandpreclinicalfindings AT zoltanpapp ayearinheartfailureupdatesofclinicalandpreclinicalfindings AT massimofpiepoli ayearinheartfailureupdatesofclinicalandpreclinicalfindings AT magnusback yearinheartfailureupdatesofclinicalandpreclinicalfindings AT stephanvonhaehling yearinheartfailureupdatesofclinicalandpreclinicalfindings AT zoltanpapp yearinheartfailureupdatesofclinicalandpreclinicalfindings AT massimofpiepoli yearinheartfailureupdatesofclinicalandpreclinicalfindings |